LTP measurements available through reMYND
11-08-2014
reMYND now offers LTP measurements to allow clients to assess the effect of their experimental Alzheimer treatment.
Read more
Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment
27-03-2014
Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment.
Read more
Tau.P301S model available at reMYND’s CRO for efficacy testing of Alzheimer treatments
27-03-2014
Over the last years, more and more tau-treatments are being assessed in mouse models for their potential to treat Alzheimer’s disease. One of the key challenges with many of the tau mouse models is the need for large numbers of animals due to their intrinsic variability.
Read more
reMYND’s Tau.P301L mice used to demonstrate efficacy of antibody treatment on behaviour and pathological read-outs
04-11-2013
In the last several years, Tau-directed therapies have gained more interest as a strategy for treating Alzheimer’s Disease.
Read more
BMS publishes paper in collaboration with reMYND showing dose-dependent effects of donepezil on brain Abeta and cognition in MWM
08-07-2013

“Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease”.

Read more
reMYND launches a project aimed at improving the predictability of preclinical Alzheimer models as part of the prestigious Marie-Curie International Training Network NPlast
06-09-2012
reMYND NV announced today its project in NPlast, a prestigious International Training Network funded by the European Commission that is to be launched April 27-28th 2012 at the Leibniz-Institut für Neurobiologie in Magdeburg, Germany.
Read more
reMYND’s CRO receives governmental grant for a continued innovation of its offering
09-05-2011
The governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization.
Read more
reMYND's CRO announces publication in the International Journal of Alzheimer's Disease
08-09-2010

New data on reMYND's proprietary mouse models of Alzheimer's disease: pathological hallmarks, clinical parallels, and value for drug testing.

Read more
reMYND and Amorfix announce agreement
06-07-2010
Amorfix Life Sciences Ltd. (TSX:AMF) and reMYND nv today announced the signing of a partnership agreement.
Read more
reMYND licenses highly innovative transgenic mouse models
20-08-2008
reMYND licenses highly innovative transgenic mouse models of Alzheimer's Disease TAU and Amyloid pathology from the University of Leuven.
Read more